arrow
I

Iain A. McNeish

Department of Surgery and Cancer
H指数:71
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism

CDK12/13抑制通过破坏RNA代谢克服铂耐药性

2026-09-030
OAAI
A tumour-derived organoid biobank maps cancer gene dependencies

肿瘤来源的类器官生物样本库绘制了癌症基因依赖图谱

Nature
IF48.5
2026-08-050
OA
Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability

亲电化合物筛选鉴定出GPX4依赖性铁死亡为衰老的易损性

2026-04-240
OAAI
Rethinking ovarian cancer III: the past decade and future directions

重新思考卵巢癌III:过去十年及未来方向

2026-04-130
PRE
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma

BRCA缺陷性输卵管卵巢高级别浆液性癌的生存临床病理及分子预测因子

2026-04-010
OAAI
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors

多模态成像揭示了一种溶酶体药物贮库,该贮库驱动PARP抑制剂分布的异质性

2026-03-170
OAAI
RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination

RAS/PI3K通路突变使上皮性卵巢癌细胞对PARP/NAMPT抑制剂组合产生敏感性

2025-12-190
OA
Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer

398,238名女性的全基因组关联研究揭示了七个与高级别浆液性卵巢癌相关的位点

2025-11-200
OAAI
Identification of actionable targets using DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded tissues followed by shallow whole-genome sequencing

通过DEPArray辅助的固定石蜡包埋组织中纯癌和基质细胞群的分选,结合浅层全基因组测序,鉴定可操作靶点

2025-10-270
OAAI
Identifying High-Risk Relapse in Early-Stage I–II Ovarian Cancer Using the CA-125 ELIMination rate constant K (KELIM) Score: A GCIG Individual Patient Data Meta-analysis

使用CA-125 ELIMination率常数K (KELIM)评分识别早期I-II期卵巢癌的高复发风险:一项GCIG个体患者数据荟萃分析

2025-10-100
OAAI
Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer

Ewing, A.; Meynert, A.; Silk, R.; Aitken, S.; Bendixsen, D.P.; Churchman, M.; Brown, S.L.; Hamdan, A.; Mattocks, J.; Grimes, G.R.; 等. 结构多样性影响高级别浆液性卵巢癌患者生存的分歧轨迹。Nat. Commun. 2025, 16, 5586. [Google Scholar] [CrossRef] [PubMed]

2025-07-010
OAAI
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment (vol 15, 1500570, 2024)

通过细胞外囊泡介导的微小RNA重编程肿瘤微环境以增强溶瘤病毒疗法 (vol 15, 1500570, 2024)

2025-04-220
OA
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors

TIMEPOINT是一项将MTL-CEBPA与pembrolizumab联合使用的I期研究,证实了MTL-CEBPA在实体瘤中的免疫调节作用。

2025-04-010
OAAI
Difference Of Chemosensitivity Between Western And Japanese Women In First-Line Setting Of Advanced Serous Ovarian Cancer: Data From The MAOV Individual Patient Data Meta-Analysis

西方与日本女性在晚期浆液性卵巢癌一线治疗中的化疗敏感性差异:来自MAOV个体患者数据Meta分析的数据

2025-02-010
PRE
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment

通过细胞外囊泡介导的microRNA重新编程肿瘤微环境来增强溶瘤病毒治疗

2024-12-230
OAAI